Incidence of relapse at 5 years
| Factor . | Relapse at 5 y (95% CI) . | P . |
|---|---|---|
| No. of units, all patients | ||
| Single | 33% (21%-45%) | 0.04 |
| Double | 19% (11%-27%) | |
| No. of units, patients in CR1-2 | ||
| Single | 31% (19%-43%) | 0.03 |
| Double | 16% (8%-24%) | |
| Disease status | ||
| ALL | 0.01 | |
| CR1 and CR2 | 21% (11%-31%) | |
| CR3 and relapsed | 40% (16%-64%) | |
| AML | ||
| CR1 and CR2 | 24% (14%-34%) | |
| CR3 and relapsed | 39% (16%-62%) | |
| Conditioning and GVHD regimen, single UCB recipients only | ||
| Cyclophosphamide/TBI methylprednisone/ATG/CSA | 33% (20%-46%) | 0.93 |
| Cyclophosphamide/fludarabine/TBI CSA/MMF | 34% (16%-52%) |
| Factor . | Relapse at 5 y (95% CI) . | P . |
|---|---|---|
| No. of units, all patients | ||
| Single | 33% (21%-45%) | 0.04 |
| Double | 19% (11%-27%) | |
| No. of units, patients in CR1-2 | ||
| Single | 31% (19%-43%) | 0.03 |
| Double | 16% (8%-24%) | |
| Disease status | ||
| ALL | 0.01 | |
| CR1 and CR2 | 21% (11%-31%) | |
| CR3 and relapsed | 40% (16%-64%) | |
| AML | ||
| CR1 and CR2 | 24% (14%-34%) | |
| CR3 and relapsed | 39% (16%-62%) | |
| Conditioning and GVHD regimen, single UCB recipients only | ||
| Cyclophosphamide/TBI methylprednisone/ATG/CSA | 33% (20%-46%) | 0.93 |
| Cyclophosphamide/fludarabine/TBI CSA/MMF | 34% (16%-52%) |